OLMA
Olema Pharmaceuticals Inc
NASDAQ · Biotechnology
$25.36
+0.35 (+1.40%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 273.28M | 252.57M | 215.43M |
| Net Income | -27,842,007 | -24,319,116 | -27,608,347 |
| EPS | — | — | — |
| Profit Margin | -10.2% | -9.6% | -12.8% |
| Rev Growth | +22.4% | +21.1% | -4.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 380.18M | 379.05M | 375.72M |
| Total Equity | 1.51B | 1.56B | 1.36B |
| D/E Ratio | 0.25 | 0.24 | 0.28 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -48,708,771 | -44,721,101 | -36,525,999 |
| Free Cash Flow | -19,743,741 | -20,820,819 | -13,833,937 |